jak2v617f allele burden measurement in peripheral blood of iranian patients with myeloproliferative neoplasms and effect of hydroxyurea on jak2v617f allele burden

background: myeloproliferative neoplasms (mpns) are clonal malignant diseases that represent a group of conditions including polycythemia vera (pv), essential thrombocythemia (et) and primary myelofibrosis (pmf). the aim of this study was to evaluate possible correlations between jak2v617f allele burden and clinicohematologic characteristics in iranian patients with mpns. we also aimed at determining the correlation between jak2v617f allele burden and use of cytoreductive treatment (hydroxyurea). materials and methods: we performed arms-pcr for all mpns samples and subsequently performed real-time quantitative polymerase chain reaction (qrt-pcr) for jak2v617f allele burden measurement using dna from peripheral blood leukocytes. results: two distinct groups of patients were examined at a single time point: group a (n=40; 20 pv, 20 et) was examined at the time of diagnosis; group b (n=85; 40 pv, 30 et and 15 pmf) while under treatment with hydroxyurea (hu). the median allele burden of the jak2 v617f was 72% for pv and 49% for et patients at the time of diagnosis (p=0.01). for patients with hu treatment, we determined the median jak2v617f allele burden to be 43%, 40%, and 46.5 % in pv, et and pmf patients; respectively. hu-treated pv patients had a significant lower %jak2v617f than pv patients at the time of diagnosis (43% vs. 72%, p=0.005). in et group, the relationship between the jak2 v617f allele burden and leukocyte count was significant (p=0.02 and p=0.01 in untreated and treated patients, respectively). conclusions: our results showed that patients with pv have a higher jak2v617f allele burden. moreover, our study demonstrated that the jak2v617f allele burden correlates with clinical features in et group. we also showed hydroxyurea can affect the jak2v617f allele burden in pv patients.